A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease | MicrobiomeTrials← Back to trialsNCT07737743
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-24Est. Completion: 2029-02-19
Enrollment target: 344 participants Locations- Clinical Research of West Florida Inc, Tampa, Florida, United States
- RAO Research LLC, Oklahoma City, Oklahoma, United States
- Novel Research LLC, Bellaire, Texas, United States
- Novartis Investigative Site, Southport, Queensland, Australia
- Novartis Investigative Site, Sherbrooke, Quebec, Canada
- Novartis Investigative Site, Kfar Saba, Israel
- Novartis Investigative Site, Petah Tikva, Israel
- Novartis Investigative Site, Ramat Gan, Israel
- Novartis Investigative Site, Ẕerifin, Israel
Other microbiome trials you might be interested in
Primary Sjögren's Syndrome
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety …
Covina, United StatesEst. completion Jul 2028
Congenital Hemolytic AnemiaSickle Cell Disease
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow…
Bethesda, United StatesEst. completion Jan 20, 2023
Phase 3
Recruiting
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneo…
Peoria, United StatesEst. completion Aug 14, 2029